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INTRODUCTION: Currently developed bone 
substitutes such as calcium-based bone cements have 
tried to overcome the clinical complications found in 
PMMA cement augmentation for osteoporotic spinal 
fracture1. However, lack of osteointegration and 
mismatched mechanical properties of PMMA 
potentially jeopardize surgical outcomes e.g. interfere 
bone healing and adjacent level fracture2. Hence, our 
group has fabricated a novel bone substitute comprised 
of polycaprolactone (PCL) and magnesium (Mg) with a 
wide range of compressive moduli and enhanced 
osteoblastic activity for vertebral cement augmentation. 
This paper aims to report the mechanical 
characteristics, in-vitro and in-vivo properties of the 
new bone substitute. 
METHODS: The bone substitutes were prepared by 
incorporating 0.1g or 0.6g silane-treated Mg particles 
into 1g PCL. Their mechanical properties were 
evaluated by compression test, whereas the 
cytocompatibility and osteogenic differentiation 
properties were studied by direct cell culture, MTT and 
ALP assays, respectively. The in-vivo response was 
studied in rat model for 6 months. The animals were 
monitored and examined by Micro-CT at respective 
time points. Commercial PMMA and pure PCL were 
served as the controls. 
RESULTS: The compressive moduli of the composites 
with 0.1g and 0.6g Mg were 1-fold and 3-fold higher 
than PCL, respectively (as shown in Figure 1). Also, 
they were about 5-fold and 2-fold lower than PMMA. 
The cell viabilities of all new composites were higher 
than 100% as compared to the control. The ALP 
activities of PMMA were significantly lower on days 3, 
7 and 14 as compared to the new composites and pure 
PCL, whereas significantly higher ALP activities were 
found on day 14 of the new composites with 0.1g Mg. 
Figure 2 shows the percentage change of bone volume 
on all the samples during the implantation period. 
Significant more new bone formation was found on 
new composites with 0.1g Mg after 1 week of post-
operation and up to 8 weeks as compared with the 
control. 
 
 
 
 
 
 
Fig. 1 (Left): Compressive moduli of the PCL-Mg 
composites as compared to PMMA & PCL (Blue box: 
range of human cancellous bone moduli). Fig. 2 (Right): 
The percentage change of bone volume during the 
implantation period. 
DISCUSSION & CONCLUSIONS: The results of in-
vitro tests suggested that the new composites were well 
tolerated by bone cells and osteoconductive. In in-vivo 
experiment, new bone formation found in the 
composite with 0.1g Mg was significantly higher than 
that of PMMA at the early time points. It indicated the 
new bone substitutes could promote fast bone healing 
as compared to the conventional PMMA. Additionally, 
various compressive moduli of the new composites can 
be adjusted by incorporating different amounts of Mg 
particles into the material matrix in which these new 
substitutes are mechanically similar to the cancellous 
bone (50-800MPa)3. Hence, they potentially help 
reduce the post-op complications while using PMMA. 
In summary, we prove that the mechanical properties of 
the newly developed bone substitutes can be 
individualized according to patient’s need. Also, the 
new composites are radiopague, biodegradable and 
injectable that benefit for clinical applications.     
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